Today: 9 April 2026
Subscribe
Browse Category

LSE:SXS 20 November 2025 - 3 December 2025

Spectris plc (LON: SXS) Stock on 3 December 2025: Last Trading Day Before £41.75 KKR Takeover and Delisting

Spectris plc (LON: SXS) Stock on 3 December 2025: Last Trading Day Before £41.75 KKR Takeover and Delisting

Spectris plc shares traded for the final time on the London Stock Exchange on 3 December 2025, closing near 4,143p, just below KKR’s £41.75 per share cash offer. The takeover, valued at about £4.2 billion, follows a year-long bidding war with Advent International. Over 99.9% of shareholders approved the KKR deal in August. The stock will be delisted later this week.
3 December 2025
···
Spectris plc (LON:SXS) on 2 December 2025: Share Price, £41.75 KKR Takeover, Latest News and Analyst Forecasts

Spectris plc (LON:SXS) on 2 December 2025: Share Price, £41.75 KKR Takeover, Latest News and Analyst Forecasts

Spectris shares traded at 4,140p early Tuesday, just 1% below KKR’s £41.75-per-share cash offer, as the takeover nears completion. The stock has risen nearly 64% in a year and now moves narrowly in merger-arbitrage territory. Regulators and index providers are preparing for the company’s expected delisting later this week. Reuters values the deal at about £4.7 billion including debt.
2 December 2025
···
Spectris Share Price on 1 December 2025: KKR £41.75 Takeover Nears the Finish Line as New Voting and Stake Disclosures Land

Spectris Share Price on 1 December 2025: KKR £41.75 Takeover Nears the Finish Line as New Voting and Stake Disclosures Land

Spectris shares traded just below KKR’s £41.75-per-share offer ahead of expected delisting from the London Stock Exchange this week. Regulatory filings show Barclays holding roughly equal long and short positions of about 5% each, with trades clustered near £41.33. The company reported 99.4 million voting rights as of November 30. The deal spread remains just over 1%.
1 December 2025
··
Spectris (SXS) Share Price Today, 27 November 2025: KKR Takeover Nears Completion as New NexPoint Filing Lands

Spectris (SXS) Share Price Today, 27 November 2025: KKR Takeover Nears Completion as New NexPoint Filing Lands

Spectris shares traded at 4,132p by late morning Thursday, less than 1% below KKR’s £41.75-per-share takeover offer. All regulatory approvals are in place, with a UK court hearing set for 2 December and delisting from the London Stock Exchange expected by 5 December. FTSE Russell will remove Spectris from major indices on 4 December.
27 November 2025
··
Spectris (LON: SXS) Share Price Today, 26 November 2025 – Fresh Stake Disclosures as KKR’s £41.75 Takeover Nears the Finish Line

Spectris (LON: SXS) Share Price Today, 26 November 2025 – Fresh Stake Disclosures as KKR’s £41.75 Takeover Nears the Finish Line

Spectris shares traded around 4,132p–4,134p in London on Monday, less than 1% below the £41.75 per share takeover offer from KKR-backed Project Aurora Bidco. Trading was subdued, with activity focused on disclosure filings including a major holdings notice from JPMorgan Chase, which lifted its economic interest above 8%. No new terms or surprises emerged.
26 November 2025
··
Spectris PLC Share Price Today (20 November 2025): LON:SXS Holds Just Below £41.75 KKR Takeover Price

Spectris PLC Share Price Today (20 November 2025): LON:SXS Holds Just Below £41.75 KKR Takeover Price

Spectris shares traded at 4,108.0p on Thursday, up 2p, with about £9.5 million in turnover. The price sits just 1.6% below the £41.75 per share cash offer from KKR. Jefferies International disclosed a 1.216% long and 1.14% short position in Spectris as of 19 November. Trading remains focused on takeover-related filings rather than company news.
20 November 2025
··

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:13 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop